Transition of CEO role
Posted on 15 May 2013
The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited.
Dr Campbell is a senior biotechnology executive with more than 20 years experience in scientific research, research management, management consulting and venture capital in Australia and internationally. After completing a PhD in plant biochemistry at Deakin University Dr Campbell held research positions in France and Australia. Following completion of an MBA at Melbourne Business School Dr Campbell worked for the international management consultancy Booz & Company before working in biotech venture capital.
Dr Campbell joined ChemGenex Pharmaceuticals in 2002, where over 9 years he became CFO, COO and Company Secretary with responsibilities ranging from finance and statutory reporting through to intellectual property management and corporate development. During his time at ChemGenex Dr Campbell was involved in M&A due diligence and implementation, capital raisings and commercial licensing deals. ChemGenex Pharmaceuticals was acquired by Cephalon, Inc. for A$230M in June 2011.
Along with Dr Greg Collier, Dr Campbell is a principal of Gemini Biotechnology, a specialist biotechnology advisory services company advising life science companies on M&A, partnering and corporate strategy.
“Through Gemini Dr Campbell has been a member of the management team of Photonz for the past year and has been involved in all partnering and corporate discussions over this period, which makes for a seamless transition of the CEO role” said Photonz' Chairman, Dr Alastair MacCormick. “We welcome James to the position of CEO and look forward to continuing to work with him as the company progresses its partnering and investment efforts”.
“This is a particularly exciting time for Photonz” said Dr Campbell. “Thanks to the ongoing understanding and support of our major shareholder, K1W1 we are on the cusp of scale-up for commercial production in the UK, and are in ongoing negotiations with a number of overseas industry partners concerning possible investment in Photonz. The due diligence processes and negotiations involved in such transactions and investment decisions are time-consuming and detailed, but the benefits will be transformational for the company.”
Dr Collier will remain a director of Photonz and will continue to be closely involved in Photonz through the consultancy contract with Gemini Biotechnology, which retains Drs James Campbell, Greg Collier and David Kyle as corporate advisers.
About Photonz: Founded in New Zealand in 2002, Photonz Corporation produces the omega-3 fatty acid eicosapentaenoic acid (EPA), which is a critical ingredient in novel therapeutics for the cardiovascular disease market. Photonz has proprietary control over a unique fermentation process involving an EPA-rich strain of marine microalgae. This has been shown to produce EPA in a range of purities up to 97% and to be suited to pharmaceutical applications. Photonz is approaching a commercial-ready phase with facilities in the UK and France involved in late-stage up-scaling of an already proven manufacturing process. EPA, which has a range of food-based and therapeutic applications, is otherwise derived from fish oil.